- Home
- CYD vs MREO Comparison
CYD vs MREO Comparison
Compare CYD & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYD
- MREO
- Stock Information
- Founded
- CYD 1951
- MREO 2015
- Country
- CYD Singapore
- MREO United Kingdom
- Employees
- CYD N/A
- MREO N/A
- Industry
- CYD Industrial Machinery/Components
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CYD Industrials
- MREO Health Care
- Exchange
- CYD Nasdaq
- MREO Nasdaq
- Market Cap
- CYD 609.7M
- MREO 281.6M
- IPO Year
- CYD 1994
- MREO N/A
- Fundamental
- Price
- CYD $41.00
- MREO $1.73
- Analyst Decision
- CYD
- MREO Strong Buy
- Analyst Count
- CYD 0
- MREO 5
- Target Price
- CYD N/A
- MREO $7.40
- AVG Volume (30 Days)
- CYD 267.4K
- MREO 910.9K
- Earning Date
- CYD 08-08-2025
- MREO 11-11-2025
- Dividend Yield
- CYD 1.29%
- MREO N/A
- EPS Growth
- CYD 40.10
- MREO N/A
- EPS
- CYD 1.66
- MREO N/A
- Revenue
- CYD $3,159,401,156.00
- MREO $500,000.00
- Revenue This Year
- CYD $6.43
- MREO N/A
- Revenue Next Year
- CYD $11.20
- MREO $55.50
- P/E Ratio
- CYD $24.31
- MREO N/A
- Revenue Growth
- CYD 17.99
- MREO N/A
- 52 Week Low
- CYD $8.61
- MREO $1.47
- 52 Week High
- CYD $41.39
- MREO $4.72
- Technical
- Relative Strength Index (RSI)
- CYD 84.09
- MREO 45.94
- Support Level
- CYD $32.71
- MREO $1.68
- Resistance Level
- CYD $33.87
- MREO $1.88
- Average True Range (ATR)
- CYD 1.65
- MREO 0.08
- MACD
- CYD 0.47
- MREO 0.01
- Stochastic Oscillator
- CYD 96.06
- MREO 31.82
About CYD China Yuchai International Limited
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International primarily operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).